Spun out of UCLA, Paganini Biopharma, Inc. had been a development stage biotechnology company focused on therapeutics for cancer. The firm was acquired in 2017 by OncoResponses. Paganini's first product had been a unique human monoclonal antibody that targets breast cancer stem cells and was being developed for triple negative breast cancer. Paganinis lead drug, ONCR-201 - a monoclonal antibody developed to target epithelial membrane protein 2, a protein shown in research to have a role in ovarian cancer. OncoResponse was itself only founded in 2015 - having been launched as a firm when Theraclone - a Seattle biotech company -and the University of Texas M.D. Anderson Cancer Center announced the formation of a new company seeking to find personalized antibodies that c/would help fight cancer.